News & Insights
A perfect partnership at The Forbury Clinic
The Lodestar DX testing system is designed for detecting pathogens in urine at clinically relevant levels – however it is…
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide…
Lodestar DX helps reduce antibiotic use at elderly care home
We’re working with Christadelphian Care Homes to help them triage residents at their always-sunny-in Swansea facility. UTIs in elderly people…
Llusern Scientific announces ISO 13485 certification
Cardiff, UK – 17 June 2025 Llusern Scientific, a point-of-care diagnostics company, announces it has been awarded ISO 13485 certification…
Llusern grabs the limelight at Arab Health 2025
Llusern Scientific exhibited the Lodestar UTI testing system outside Europe for the first time in January this year when the…
Study shows Lodestar DX accurately identifies uropathogens in mixed growth cultures
A new abstract published in JAC-Antimicrobial Resistance demonstrates that the Lodestar DX UTI testing system can ‘accurately identify the common…
Llusern secures pre-Seed investment from DBW
The Development Bank of Wales has taken an equity stake in Cardiff-based Llusern Scientific as part of a substantial six-figure…
Llusern’s Lodestar DX Evaluation Published in JAC-AMR: Demonstrating High Correlation with Gold Standard UTI Testing
This peer-reviewed study explores the potential of Lodestar DX, utilising loop-mediated isothermal amplification (LAMP) technology, to rapidly and accurately diagnose…
Longitude Prize on AMR
And winner is… It was a case of so very near and yet so far for Llusern Scientific at the…
Bio 2024, San Diego
Llusern Scientific will be taking its first steps onto American soil in June of this year. We will be attending…
Two abstracts published by JAC-AMR
Two abstracts written by Llusern researchers that discuss the need for better point-of-care diagnostics for UTIs have been published by…
Poster presentations at BSAC UTI conference
Llusern Scientific is delighted to announce that two abstracts have been accepted for poster presentation at the British Society for…
Start a conversation with Llusern
Llusern is developing treatment-directing diagnostics for high-volume healthcare challenges, starting with rapid molecular UTI testing. To learn more about the company, the product and the opportunity ahead, speak to the Llusern team.